glycoprotein iib/iiia

Lefradafiban（BIBU-104） 是一种口服血小板糖蛋白 IIb IIIa 受体拮抗剂，可用于研究心绞痛和急性冠状动脉综合症。

Tirofiban（MK383） hydrochloride monohydrate是一种非肽类糖蛋白IIb IIIa 的拮抗剂。

Gantofiban是一种糖蛋白 IIb IIIa（GP IIb IIIa）拮抗剂，可用于治疗心血管疾病，可用于研究血栓形成。

Roxifiban 是XV459的前药，是一种抗血小板剂，对血小板糖蛋白IIb IIIa 复合物(GPIIb IIIa)受体具有高亲和力和特异性。

platelet fibrinogen receptor glycoprotein IIb IIIa (GpIIb IIIa) antagonist

L-739758 is a glycoprotein IIb IIIa inhibitor.

Collagen-IN-1 (compound 3) is an ortho-carbonyl hydroquinone derivative exhibiting selective inhibition of collagen. It non-competitively inhibits agonist-induced platelet aggregation, with an IC50 value of 1.77 μM. Collagen-IN-1 effectively reduces the expression of P-selectin, activation of glycoprotein IIb IIIa, and release of adenosine triphosphate and CD63 from platelets. This compound holds promise for research into platelet-related thrombosis diseases [1].

SKF 106760 is used as a glycoprotein IIb IIIa antagonist.

Fradafiban binds to the human platelet GP IIb IIIa complex with a Kd value of 148 nM. Fradafiban is a non-polypeptide platelet glycoprotein IIb IIIa antagonist.

Sibrafiban (RO 48-3657) 是一种 Ro 44-3888 的口服非肽双前药，是一种选择性的糖蛋白 IIb IIIa 受体 (glycoprotein IIb IIIa receptor) 拮抗剂。Sibrafiban 能够抑制血小板聚集。

Batifiban, a glycoprotein IIb/IIIa antagonist, is used potentially for the treatment of coronary artery disease.

Lotrafiban hydrochloride is an platelet glycoprotein IIb IIIa blocker with oral activity.

Tirofiban HCl is an antagonist of platelet glycoprotein-IIb IIIa receptor.

AR-H067637 is a rapid-binding, reversible and potent (inhibition constant K(i) = 2-4 nM), competitive inhibitor of thrombin, as well as of thrombin bound to fibrin (clot-bound thrombin) or to thrombomodulin. The total amount of free thrombin generated in

Lamifiban is a nonpeptide glycoprotein IIb/IIIa antagonist. It prevents platelet loss during experimental cardiopulmonary bypass.

Fradafiban (BIBU-52) hydrochloride 是一种非肽血小板糖蛋白 IIb IIIa 复合体拮抗剂，其与人血小板 GP IIb IIIa 复合体结合，Kd 值为 148 nM。

DMP 728 is an antagonist of Glycoprotein IIb-IIIa.

SR121566A is a novel non-peptide antagonist of Glycoprotein IIb IIIa (GP IIb-IIIa).

GPRP (Gly-Pro-Arg-Pro) 是一种纤维蛋白聚合抑制剂，能够抑制纤维蛋白原与血小板膜糖蛋白 Ⅱb IIIa 复合物(糖蛋白 IIb IIIa 受体)之间的相互作用。

TAK 029 is a local glycoprotein IIb IIIa receptor inhibitor.

Variabilin, a novel inhibitor of human platelet aggregation, it is a potent RGD (Arg-Gly-Asp)-containing antagonist of the fibrinogen receptor glycoprotein IIb-IIIa (GPIIb-IIIa; αIIbβ3) and the vitronectin receptor αvβ3.Variabilin is also an antimicrobial furanosesterterpene. Variabilin is an inhibitor of human secretory and cytosolic phospholipase A2 (PLA2) activities that controls eicosanoid production in vitro and in vivo, inhibits neutrophil degranulation and superoxide generation in vitro and shows anti-inflammatory activity after topical or p.o. administration to mice.

Abciximab (C7E3) 是一种小鼠 人嵌合单克隆抗体，是一种有效的糖蛋白 IIb IIIa (glycoprotein IIb IIIa) 抑制剂。 Abciximab 具有抗血小板聚集和白细胞粘附的作用，通过与糖蛋白 IIb IIIa、vitronectin 和 Mac-1 受体结合发挥作用。

GPRP acetate (Pefabloc FG) 是纤维蛋白聚合抑制剂，可抑制纤维蛋白原与血小板膜糖蛋白 Ⅱb IIIa 复合物(糖蛋白 IIb IIIa 受体)之间的相互作用。

Potent irreversible αVβ3 integrin antagonist (Ki = 0.27 nM). Disrupts attachment of osteoclasts to bone and inhibits bone reabsorption (IC50 = 0.1 nM). Prevents ADP-induced platelet aggregation via inhibition of glycoprotein IIb IIIa (GpIIb IIIa, αIIbβ3)